The US Food and Drug Administration (FDA) issued a statement calling on Genervon Biopharmaceuticals to release complete data from their recent trial evaluating an experimental drug for treatment of amyotrophic lateral sclerosis (ALS). The agency is prohibited by law from releasing confidential information about experimental drugs, however the agency requested …